CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission.
Published on November 1, 2019
![[htbx_corresp002.gif]](htbx_corresp002.gif)
Heat Biologics, Inc.
677 Davis Drive
Morrisville, North Carolina 27560
November 1, 2019
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attention: Mr. Paul Fischer
|
Re: Heat Biologics, Inc. |
|
|
Registration Statement on Form S-1 |
|
|
File No. 333-234105 |
|
Dear Mr. Fischer:
Heat Biologics, Inc. (the Company) hereby requests that the effective date of the Companys Registration Statement on Form S-1, as amended (File No. 333-234105), be accelerated by the U.S. Securities and Exchange Commission to Tuesday, November 5, 2019 at 5:00 pm, New York City Time, or as soon as reasonably practicable thereafter.
The Company hereby authorizes its legal counsel, Patrick Egan and Leslie Marlow of Gracin & Marlow, LLP, to modify or withdraw (orally or in writing) this request for acceleration. Please contact Mr. Egan at (914) 557-5574 or Ms. Marlow at (516) 496-2223 or (212) 907-6457 with any questions you may have concerning this request, and please notify either of them when this request for acceleration has been granted.
|
|
|
|
|
Very truly yours, |
|
|
|
|
|
|
|
Heat Biologics, Inc. |
|
|
|
|
|
|
|
|
|
|
|
By: |
/s/ Jeffrey Wolf |
|
|
|
Name: Jeffrey Wolf |
|
|
|
Title: Chief Executive Officer |
cc: Leslie Marlow, Gracin & Marlow, LLP
Patrick Egan, Gracin & Marlow, LLP